Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Savroop Purewal has worked on the following 16 EPO patent applications which have been published in the last five years:

EP11709692

PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV

IPC classification:
C07C 51/487, C07C 61/06, C07C 69/74, C07C 235/40
Applicant:
Janssen Pharmaceuticals Inc.
Agent:
Savroop Purewal, Janssen Pharmaceutica N.V.
Status:
GRANT OF PATENT INTENDED
EP11715219

COMBINATION OF A MACROCYCLIC INHIBITOR OF HCV, A NON-NUCLEOSIDE AND A NUCLEOSIDE

IPC classification:
A61K 31/427, A61K 31/4709, A61K 31/506, A61K 31/55, A61P 31/12
Applicant:
Janssen Pharmaceuticals Inc.
Agent:
Savroop Purewal, Janssen Pharmaceutica N.V.
Status:
GRANT OF PATENT INTENDED
EP12750575

ANTIBACTERIAL PIPERIDINYL SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES

IPC classification:
A61K 31/4375, A61P 31/04, C07D 471/04
Applicant:
Janssen Research & Development Ireland
Applicant:
Janssen Sciences Ireland UC
Agent:
Savroop Purewal, Janssen Pharmaceutica N.V.
Status:
GRANT OF PATENT INTENDED
EP12746093

ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES

IPC classification:
A61K 31/4375, A61P 31/04, C07D 471/04, C07D 487/04
Applicant:
Janssen Research & Development Ireland
Applicant:
Janssen Sciences Ireland UC
Agent:
Savroop Purewal, Janssen Pharmaceutica N.V.
Status:
GRANT OF PATENT INTENDED
EP12744016

ANTIBACTERIAL HOMOPIPERIDINYL SUBSTITUTED 3,4 DIHYDRO 1H [1,8]NAPHTHYRIDINONES

IPC classification:
A61K 31/4375, A61P 31/04, C07D 471/04
Applicant:
Janssen Research & Development Ireland
Applicant:
Janssen Sciences Ireland UC
Agent:
Savroop Purewal, Janssen Pharmaceutica N.V.
Status:
GRANT OF PATENT INTENDED
EP12762583

PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV

IPC classification:
C07D 311/06, C07D 417/04, C07D 453/04
Applicant:
Janssen Pharmaceuticals Inc.
Agent:
Savroop Purewal, Janssen Pharmaceutica N.V.
Status:
EXAMINATION IN PROGRESS
EP12790677

IMPROVED PROCESS FOR PREPARING AN INTERMEDIATE OF THE MACROCYCLIC PROTEASE INHIBITOR TMC 435

IPC classification:
C07D 417/14
Applicant:
Janssen Pharmaceuticals Inc.
Agent:
Savroop Purewal, Janssen Pharmaceutica N.V.
Status:
EXAMINATION IN PROGRESS
EP14170114

HIV inhibiting 5,6-substituted pyrimidines

IPC classification:
A61K 31/505, A61K 31/506, A61P 31/18, C07D 239/48, C07D 401/04, C07D 401/06, C07D 401/12, C07D 405/04, C07D 405/12, C07D 409/04, C07D 409/12, C07D 417/06
Applicant:
Janssen Research & Development Ireland
Applicant:
Janssen Sciences Ireland UC
Agent:
Savroop Purewal, Janssen Pharmaceutica N.V.
Status:
PATENT GRANTED
EP13720875

ANTIBACTERIAL QUINOLINE DERIVATIVES

IPC classification:
A61K 31/4709, A61P 31/06, C07D 401/06, C07D 401/14
Applicant:
Janssen Pharmaceutica N.V.
Agent:
Savroop Purewal, Janssen Pharmaceutica N.V.
Status:
PATENT GRANTED
EP13719524

ANTIBACTERIAL QUINOLINE DERIVATIVES

IPC classification:
A61K 31/4709, A61P 31/06, C07D 401/06
Applicant:
Janssen Pharmaceutica N.V.
Agent:
Savroop Purewal, Janssen Pharmaceutica N.V.
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13762752

NEW ANTIBACTERIAL COMPOUNDS

IPC classification:
A61K 31/55, A61K 31/5513, A61P 31/04, C07D 401/06, C07D 401/14, C07D 405/14, C07D 413/14, C07D 471/04, C07D 498/04, C07D 498/14, C07D 513/14
Applicant:
Janssen Sciences Ireland UC
Agent:
Savroop Purewal, Janssen Pharmaceutica N.V.
Status:
PATENT GRANTED
EP13747399

NEW ANTIBACTERIAL COMPOUNDS

IPC classification:
A61K 31/551, A61P 31/04, C07D 401/06, C07D 401/12, C07D 401/14, C07D 405/12, C07D 409/14, C07D 417/14, C07D 471/04, C07D 471/14, C07D 498/04, C07D 498/14, C07D 519/00
Applicant:
Janssen Sciences Ireland UC
Agent:
Savroop Purewal, Janssen Pharmaceutica N.V.
Status:
EXAMINATION IN PROGRESS
EP15158049

Macrocylic inhibitors of hepatitis c virus

IPC classification:
A61K 31/427, A61K 31/4709, A61K 38/05, A61K 38/21, A61K 45/06, C07C 211/45, C07D 245/04, C07D 277/56, C07D 417/04, C07D 417/14, C07D 487/04
Applicant:
Janssen Sciences Ireland UC
Agent:
Savroop Purewal, Janssen Pharmaceutica N.V.
Status:
GRANT OF PATENT INTENDED
EP13722329

PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL DISEASES

IPC classification:
A61K 31/505, A61K 31/506, A61P 31/04, C07D 239/26, C07D 239/42, C07D 401/04, C07D 403/04, C07D 405/14, C07D 409/14
Applicant:
Janssen Sciences Ireland UC
Agent:
Savroop Purewal, Janssen Pharmaceutica N.V.
Status:
EXAMINATION IN PROGRESS
EP14708885

PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT

IPC classification:
A61K 31/519, A61P 29/00, A61P 35/00, C07D 487/04
Applicant:
Janssen Pharmaceutica N.V.
Agent:
Savroop Purewal, Janssen Pharmaceutica N.V.
Status:
EXAMINATION IN PROGRESS
EP16195560

AMORPHOUS SALT OF A MACROCYCLIC INHIBITOR OF HCV

IPC classification:
A61K 9/14, A61K 31/47, A61K 31/4725, A61P 31/14, C07D 417/04, C07D 417/14
Applicant:
Janssen Pharmaceuticals Inc.
Agent:
Savroop Purewal, Janssen Pharmaceutica N.V.
Status:
APPLICATION PUBLISHED

Please Sign in to use this feature